Atara Biotherapeutics Announces Changes to Its Board of Directors
Atara Biotherapeutics announced the departure of Carol Gallagher from its Board of Directors after 13 years of service. The company simultaneously appointed Brian Cherry to the board, citing his 25+ years of experience in private equity and capital allocation.
Key figures
- Cherry investment value
- $25 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.